Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Karyopharm Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $7 From $8
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
Karyopharm Therapeutics(KPTI.US) Director Sells US$785.03K in Common Stock
Karyopharm Therapeutics(KPTI.US) Director Sells US$880.69K in Common Stock
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Express News | Karyopharm Therapeutics Files For Shelf Registration Of Up To 45.8M Shares Of Common Stock By Selling Stockholders
Express News | Karyopharm Therapeutics Inc Files for Shelf of up to 45.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Karyopharm Therapeutics Analyst Ratings
Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials
Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Express News | Karyopharm Therapeutics Inc : Leerink Partners Cuts Target Price to $2 From $3
Karyopharm Therapeutics | 10-Q: Quarterly report
Karyopharm Announces Significant Refinancing Transactions
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review